|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2003-9-26
|
|
pubmed:abstractText |
Calcineurin inhibitor-induced central nervous system toxicities are uncommon and often resolve after discontinuation of the offending drug. The long-term outcome of these patients is, however, unknown. Resolution of symptoms occurred in 70% of 30 allografted recipients who developed calcineurin inhibitor-induced neurotoxicity. When patients were rechallenged with the same or a different calcineurin inhibitor, symptoms recurred in 41%, leading to permanent discontinuation of the drug. De novo or progressive acute graft-versus-host disease (GVHD) was observed in 54% of patients at a median of 7 d (range 1-70 d) after initial onset of neurotoxicity. The prognosis was grim, with 24 (80%) of these patients dying a median 33 d after the onset of neurotoxicity (range 2-594 d). GVHD and/or infection occurred in 54% and were the most common primary causes of death. We conclude that calcineurin inhibitor-induced neurotoxicity is frequently reversible but associated with a poor prognosis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0007-1048
|
|
pubmed:author |
pubmed-author:AdkinsDouglasD,
pubmed-author:BlumWilliamW,
pubmed-author:BrownRandyR,
pubmed-author:ChohanRizwanaR,
pubmed-author:DevineStevenS,
pubmed-author:DiPersioJohn FJF,
pubmed-author:GoodnoughLawrence TLT,
pubmed-author:GraubertTimothyT,
pubmed-author:KhouryHannaH,
pubmed-author:TomassonMichaelM,
pubmed-author:VijRaviR
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
123
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
110-3
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:14510951-Adult,
pubmed-meshheading:14510951-Bone Marrow Diseases,
pubmed-meshheading:14510951-Bone Marrow Transplantation,
pubmed-meshheading:14510951-Brain,
pubmed-meshheading:14510951-Calcineurin,
pubmed-meshheading:14510951-Central Nervous System Diseases,
pubmed-meshheading:14510951-Cyclosporine,
pubmed-meshheading:14510951-Female,
pubmed-meshheading:14510951-Graft vs Host Disease,
pubmed-meshheading:14510951-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:14510951-Humans,
pubmed-meshheading:14510951-Immunosuppressive Agents,
pubmed-meshheading:14510951-Magnetic Resonance Imaging,
pubmed-meshheading:14510951-Male,
pubmed-meshheading:14510951-Methotrexate,
pubmed-meshheading:14510951-Middle Aged,
pubmed-meshheading:14510951-Prednisone,
pubmed-meshheading:14510951-Retrospective Studies,
pubmed-meshheading:14510951-Tacrolimus,
pubmed-meshheading:14510951-Transplantation, Homologous
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity.
|
|
pubmed:affiliation |
Washington University School of Medicine, Department of Medicine, Division of Oncology, Section of Leukaemia & Bone Marrow Transplantation, St Louis, MO 63110-1093, USA.
|
|
pubmed:publicationType |
Journal Article
|
